Heartflow, Inc. $HTFL Shares Acquired by Royal Bank of Canada

Posted by Francis Steltz on Aug 16th, 2026

Royal Bank of Canada increased its position in shares of Heartflow, Inc. (NASDAQ:HTFL – Free Report) by 24.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,421 shares of the company’s stock after purchasing an additional 26,912 shares during the quarter. Royal Bank of Canada’s holdings in Heartflow were worth $3,343,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Rock Springs Capital Management LP increased its stake in Heartflow by 106.2% during the first quarter. Rock Springs Capital Management LP now owns 572,500 shares of the company’s stock valued at $13,929,000 after purchasing an additional 294,800 shares during the last quarter. Quantinno Capital Management LP bought a new position in shares of Heartflow in the 1st quarter worth about $1,734,000. Lazard Asset Management LLC acquired a new position in shares of Heartflow in the 1st quarter valued at about $928,000. Entropy Technologies LP acquired a new position in shares of Heartflow in the 1st quarter valued at about $338,000. Finally, Sei Investments Co. grew its position in shares of Heartflow by 342.5% during the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock valued at $1,631,000 after buying an additional 51,895 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on HTFL shares. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday. Stifel Nicolaus increased their price target on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday. Freedom Capital raised Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.43.

Get Our Latest Research Report on Heartflow

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Heartflow Stock Up 35.7%

Heartflow stock opened at $42.08 on Friday. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $43.00. The firm has a market capitalization of $3.63 billion and a price-to-earnings ratio of -22.99. The firm has a 50-day moving average price of $29.08 and a two-hundred day moving average price of $27.80.

Heartflow (NASDAQ:HTFL – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Research analysts expect that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Insider Buying and Selling

In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the transaction, the insider owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of Heartflow stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the transaction, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This represents a 7.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 115,805 shares of company stock valued at $3,530,609 over the last three months. Corporate insiders own 7.70% of the company’s stock.

Heartflow Profile

(Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.